Nervous system drugs taken by future fathers and birth defects in offspring: a prospective registry-based cohort study

Maarten Wensink, Ying Lu, Lu Tian, Tina Kold Jensen, Niels Erik Skakkebæk, Rune Lindahl-Jacobsen, Michael Eisenberg

ABSTRACT

Objectives To evaluate the association of paternal intake of antipsychotics, anxiolytics, hypnotics and sedatives, antidepressants, selective serotonin reuptake inhibitors (SSRIs) and (benzodiazepines during the development of fertilising sperm with birth defects in offspring.

Design Prospective registry-based cohort study.

Setting Total Danish birth cohort 1997–2016 using Danish national registries.

Participants All 1 201 119 Danish liveborn singletons born 1997–2016 were eligible, 39 803 (3.3%) of whom had at least one major birth defect.

Exposure Offspring were considered exposed if their father had filled at least one prescription in the relevant drug category during development of fertilising sperm (the 3 months prior to conception).

Primary and secondary outcome measures Primary outcome was the diagnosis, in the first year of life, of at least one major birth defect as categorised in the EUROCAT guidelines. Secondary outcome was the diagnosis, in the first year of life, of at least one major birth defect in any of the EUROCAT subcategories. Adjusted ORs (AORs) were calculated, along with their 95% CIs, adjusted for year, education, smoking status and age of the mother, and education, disposable income and age of the father.

Results This study found weak or null associations between birth defects and selected drugs. Specifically, antidepressants (17 827 exposed births) gave 3.5% birth defects (AOR 0.97 (0.89 to 1.05)). Diazepines, oxazepines, thiadiazepines and oexepines (as antipsycotics, 1633 offspring) gave 4.7% birth defects (AOR 1.22 (0.97 to 1.54)), attenuated to 1.13 when excluding by mothers’ prescriptions. The study was well powered assuming 100% therapy adherence, while assuming 50% therapy adherence. In particular, it is unknown whether paternal use of these drugs during sperm development is associated with the risk of birth defects.

INTRODUCTION

Certain neurological drugs have been associated with adverse changes in semen quality. Beyond common reproductive outcomes like sperm motility, selective serotonin reuptake inhibitors (SSRIs) have been associated with increased frequencies of DNA fragmentation and abnormal sperm morphology. Anxiolytics, in particular benzodiazepines, have been associated with chromosomal abnormalities in sperm. Of concern, many of these drugs are commonly prescribed to prospective fathers with increasing use over time. In Denmark, the proportion of births where the father had been prescribed neurological drugs in the 6 months preceding conception more than doubled between 1997 and 2017, from approximately 4% to almost 9%. Importantly, prescriptions of antidepressants, mostly SSRIs, increased threefold to 2.5%.

It is known that paternal factors are associated with birth outcomes such as preterm birth, low birth weight and neonatal intensive care unit stays. Given the association of sperm DNA damage in certain neurological drugs, the safety of neurological drugs regarding offspring health needs to be evaluated. In particular, it is unknown whether paternal use of these drugs during sperm development is associated with the risk of birth defects.

Hence, we performed a cohort study on all singleton live births in Denmark 1997–2016 (1 201 119 births), linking national registries: the birth registry, the prescription registry and the patient registry. We then assessed for any association between specific neurological drugs prescribed to the father to be in the 3 months just prior to conception (sperm...
Table 1  Cohort characteristics by drug use for all liveborn singletons in Denmark 1997–2016

| None of the specified drugs (1 147 005) | Antipsychotics (4301) | Anxiolytics (4918) | Hypnotics and sedatives (5797) | Antidepressants (17 827) | (benzo) Diazepines(7057) |
|----------------------------------------|-----------------------|--------------------|-------------------------------|--------------------------|--------------------------|
| Age father, years (mean (Q1–Q3))       | 33.0 (29.2–35.6)      | 34.3 (29.0–38.7)   | 36.0 (30.9–40.4)              | 36.4 (31.5–40.6)         | 34.6 (30.2–38.4)         |
| Age mother, years (mean (Q1–Q3))       | 30.4 (27.2–33.7)      | 30.0 (25.8–34.0)   | 31.0 (27.2–34.8)              | 31.3 (27.5–35.1)         | 31.0 (27.4–34.6)         |
| Gestation age, days (mean (Q1–Q3))     | 279 (273–287)         | 277 (272–286)      | 277 (272–286)                 | 277 (272–286)            | 278 (272–286)            |
| Pre-term (% (N))                       | 5.0% (57 395)         | 6.7% (288)         | 6.5% (319)                    | 6.2% (357)               | 5.8% (1027)              |
| Birth weight, kg (mean (Q1–Q3))        | 3.5 (3.2–3.9)         | 3.4 (3.1–3.8)      | 3.4 (3.1–3.8)                 | 3.5 (3.2–3.9)            | 3.4 (3.1–3.8)            |
| Birth length, cm (mean (Q1–Q3))        | 55 (50–54)            | 51 (50–53)         | 52 (50–53)                    | 52 (50–53)               | 51 (50–53)               |
| Apgar score <8 (% (N))                 | 1.3% (15 001)         | 1.7% (73)          | 1.6% (78)                     | 1.3% (74)                | 1.6% (288)               |
| Low education father (% (N))           | 19.0% (213 009)       | 44.8% (1928)       | 38.8% (1908)                  | 32.3% (1872)             | 28.6% (5101)             |
| High education father (% (N))          | 12.0% (136 825)       | 5.6% (241)         | 7.3% (358)                    | 10.6% (614)              | 9.4% (1678)              |
| Low education mother (% (N))           | 18.0% (204 933)       | 40.4% (1737)       | 35.2% (1730)                  | 31.0% (1799)             | 24.8% (4423)             |
| High education mother (% (N))          | 11.0% (124 850)       | 5.2% (225)         | 6.2% (306)                    | 8.8% (507)               | 9.2% (1637)              |
| Mother quit smoking (% (N))            | 2.0% (26 752)         | 4.0% (171)         | 3.1% (151)                    | 2.5% (146)               | 3.2% (569)               |
| Mother smoked (% (N))                  | 12.0% (138 007)       | 25.0% (1075)       | 26% (1281)                    | 20.1% (1164)             | 17.8% (3176)             |
| Income father (mean (Q1–Q3))           | 205 (138–248)         | 147 (104–172)      | 158 (101–191)                 | 183 (106–218)            | 181 (119–224)            |
| Parity 0 (% (N))                       | 45.6% (523 304)       | 45.7 (1967)        | 41.3% (2030)                  | 42.6% (2467)             | 41.6% (7414)             |
| Parity 1 (% (N))                       | 37.2% (426 557)       | 30.5% (1313)       | 33.4% (1643)                  | 32.7% (1898)             | 36.2% (6450)             |
| Parity 2 (% (N))                       | 13.2% (151 369)       | 15.4% (662)        | 15.8% (775)                   | 15.5% (899)              | 15.3% (2727)             |
| Parity 3 or more (% (N))               | 4.0% (45 825)         | 8.3% (359)         | 9.6% (470)                    | 9.2% (533)               | 6.9% (1236)              |
| Boys (% (N))                           | 51.4% (583 062)       | 50.8% (2185)       | 51.7% (2544)                  | 51.4% (2979)             | 51.6% (9204)             |
| Major birth defect (% (N))             | 3.3% (38 194)         | 3.9% (167)         | 3.5% (173)                    | 3.3% (190)               | 3.5% (617)               |

% are column percentages. Group 'none of the specified drugs' refers to no drugs that occur in the other columns. Other columns may overlap. In particular, benzo(diazepines) are subgroups of antipsychotics (N05A), anxiolytics (N05B) and hypnotics and sedatives (N05C). Income father refers to disposable income in thousands of Danish crowns per year. n, number; Q, quartile.
development) and birth defects diagnosed in the first year of life.

**METHODS**

**Data and inclusion criteria**

We obtained the Danish Medical Birth Registry (MFR) 1997–2016, which contains all births in Denmark from 20 weeks of gestation onwards. In addition to characteristics of the newborn and pregnancy, such as gestational age and Apgar score, this registry contains the CPR (Centrales Personregister) number, a unique identifier that all Danish citizens and residents have been given since 1968, for newborn, mother and father (if known). We used this CPR number to link registries, meaning that entries with unusable or missing CPR number of either parent or offspring were deleted. Stillbirths were also deleted due to dissimilar ascertainment of birth defects (see Outcome). Approximate conception date is contained in the MFR as birth date minus estimated gestational age.

We linked this registry to the Danish National Prescription Registry (LMDB), which we obtained from 1995 to mid-2018. This registry gives complete coverage of all prescriptions filled in Denmark by persons with a CPR number. In Denmark, over-the-counter drug prescriptions are limited; common pain medication like paracetamol is not freely available in large packages. From this registry, we created indicator variables for exposure (see Exposure). We also used this registry to identify those births where the mother had taken any of the investigated drugs up to giving birth (see Statistical Analyses).

We further linked with the Danish National Patient Registry from 1995 through mid-2018, which contains diagnoses for inpatient and outpatient contacts, although not for diagnoses in the family doctor setting. This registry includes birth defects, which we classified according to the EUROCAT guidelines, allowing 1 year of follow-up on birth. Birth defects that EUROCAT classified as minor were excluded.

We incorporated information from Statistics Denmark, the central authority on Danish statistics. These variables were paternal disposable income, the amount of money that a person or household has available for spending and saving after income taxes and interest expenses have been accounted for, and highest achieved education (both by year). We further linked with the Population Registry to obtain birth date and sex of the parents. Births with fathers of unknown or female sex were removed, as were births to mothers of male sex.

**Outcome**

The primary outcome was the diagnosis of at least one major birth defect in the first year of life (binary variable), categorised as per the EUROCAT guidelines, which provide International Classification of Diseases (ICD) codes of birth defects that they classify as major. The secondary outcome was being diagnosed with at least one major birth defect (binary variable) in any of the EUROCAT subcategories (by organ or tract).

**Exposure**

As one spermatogenic cycle takes approximately 3 months, we considered offspring whose father filled a prescription in the relevant category during the 3 months preconception as exposed. We examined the following medication categories: antipsychotics (Anatomical Therapeutic Chemical classification code N05A), among which diazepines, oxazepines, thiazepines and oxepines (N05AH); anxiolytics (N05B), among which benzodiazepine-derived anxiolytics (N05BA); hypnotics and sedatives (N05C), among which benzodiazepines (N05CD); and antidepressants (N06A), among which SSRIs (N06AB).

**Missing data**

Approximately 15% of the merged records had at least one entry missing, in particular maternal smoking status (online supplemental table 1). We imputed 10 datasets in a procedure described in detail in the Statistical appendix under the assumption of missingness at random. Reported results are estimates and SEs pooled under Rubin’s rule. Imputation and pooling was handled with the R package mice (V.3.8.0).

**Statistical analyses**

We employed flexible logistic regressions using generalised additive models with R package mgcv V.1.8–33, which allow non-linear smooth associations between the exposure variable and the birth defect risk. Categorical variables were modelled by simple indicator variables for each level. From these models, we obtained ORs and their 95% CIs for being diagnosed with at least one major birth defect in the first year of life after adjusting for birth year, maternal factors (smoking status during pregnancy, highest achieved education, maternal age) and paternal factors (disposable income, highest achieved education and paternal age). These potential confounders were selected prior to the analysis for their potential relatedness to both the predictor and outcome and were not selected based on their significance.

We compared exposed versus unexposed groups for each drug group separately, first for all liveborn singletons. As a sensitivity analysis, we then repeated this analysis excluding births where the mother had taken any of the investigated drugs at any time prior to delivery. We then compared, by conditional logistic regression, exposed versus unexposed offspring of the same father, adjusting for birth year, maternal age, and nulliparity. We then analysed the distribution across EUROCAT organ subgroups without excluding births based on maternal drug use. All data analyses were carried out on the secure server of Statistics Denmark and run in R V.3.6.3.

**Minimum detectable risk and OR calculations**

We calculated minimum detectable ORs at 80% and 90% power using the software PS Power and Sample Size, V.3.1.6 both for the actual exposure numbers and under the assumption that 50% of the fathers actually took their...
prescriptions. Because some drugs induced highly selective groups (see Results), we conservatively assumed an exposed:unexposed ratio of 1:10 for these calculations (the larger groups tended to be less selective, see Results).

**Patient and public involvement statement**

Patients or the public were not involved in the planning, executing and communication of this study.

**RESULTS**

**The cohort**

The Birth Register had 1276229 records for 1997–2016. After exclusion of records with unusable CPR of the offspring (2888) or father (1150), 1272750 records could be linked to the patient register, the prescription register, (socioeconomic) variables held at Statistics Denmark and the population register. Excluding births to fathers with registered unknown or female sex (19163), mothers of male sex (7), and stillbirths (1927) left 1251653 records for multiple imputation. After imputation, excluding records of non-singleton births (50534) and records with missing gestational age (27080) left 1174727 offspring. Exclusion of births with mothers who filled a prescription of any of the investigated drugs at any time up to delivery left 936706 offspring.

Among the 1174727 births available for the main analysis, that is, liveborn singletons without missing gestational age, 17827 offspring were exposed to antidepressants, including 11902 to SSRIs; 4301 to antipsychotics, including 1633 to diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH)

### Table 2 Specific neurological drugs associated with sperm damage and their adjusted ORs (AORs) for having at least one major birth defect

| Drug class | Number of offspring | Number of fathers | Birth defects | AOR | 95% CI |
|------------|---------------------|-------------------|---------------|-----|--------|
| Antipsychotics (N05A) | 4301 | – | 3.9% (167) | 1.07 | 0.92 to 1.25 |
| After exclusion | 2950 | – | 3.3% (85) | 0.95 | 0.77 to 1.18 |
| Sibling analysis | 5437 | 1971 | 3.4% versus 3.2% | 1.00 | 0.74 to 1.37 |
| Anxiolytics (N05B) | 4918 | – | 3.5% (173) | 1.07 | 0.92 to 1.24 |
| After exclusion | 3153 | – | 3.2% (102) | 1.03 | 0.85 to 1.26 |
| Sibling analysis | 6196 | 2379 | 3.4% versus 3.1% | 1.08 | 0.82 to 1.43 |
| Hypnotics and sedatives (N05C) | 5797 | – | 3.3% (190) | 0.96 | 0.83 to 1.12 |
| After exclusion | 3706 | – | 3.2% (119) | 0.99 | 0.83 to 1.19 |
| Sibling analysis | 8478 | 3220 | 3.1% versus 3.2% | 0.97 | 0.76 to 1.25 |
| Diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH) | 1633 | – | 4.7% (76) | 1.22 | 0.97 to 1.54 |
| After exclusion | 902 | – | 4.1% (37) | 1.13 | 0.81 to 1.57 |
| Sibling analysis | 2220 | 812 | 4.1% versus 3.2% | 1.24 | 0.76 to 2.02 |
| Benzodiazepine-derived anxiolytics (N05BA) | 4742 | – | 3.5% (166) | 1.06 | 0.91 to 1.24 |
| After exclusion | 3047 | – | 3.2% (97) | 1.02 | 0.83 to 1.25 |
| Sibling analysis | 5885 | 2266 | 3.3% versus 3.1% | 1.06 | 0.79 to 1.41 |
| Benzodiazepines as hypnotics and sedatives (N05CD) | 1153 | – | 3.1% (36) | 0.96 | 0.69 to 1.34 |
| After exclusion | 736 | – | 2.9% | 0.93 | 0.60 to 1.43 |
| Sibling analysis | 1495 | 545 | 2.9% versus 3.4% | 0.88 | 0.49 to 1.59 |
| (Benzo)diazepines grouped (N05AH, N05BA or N05CD) | 7057 | – | 3.6% (254) | 1.06 | 0.93 to 1.20 |
| After exclusion | 4428 | – | 3.3% (147) | 1.03 | 0.87 to 1.22 |
| Sibling analysis | 8777 | 3318 | 3.3% versus 3.3% | 1.02 | 0.80 to 1.29 |
| Antidepressants (N06A) | 17827 | – | 3.5% (617) | 0.97 | 0.89 to 1.05 |
| After exclusion | 11487 | – | 3.2% (372) | 0.95 | 0.85 to 1.05 |
| Sibling analysis | 23400 | 9020 | 3.3% versus 3.6% | 1.02 | 0.87 to 1.19 |
| SSRIs (N06AB) | 11902 | – | 3.3% (397) | 0.94 | 0.85 to 1.04 |
| After exclusion | 7751 | – | 3.3% (254) | 0.96 | 0.85 to 1.09 |
| Sibling analysis | 15971 | 6220 | 3.2% versus 3.6% | 0.93 | 0.77 to 1.11 |

All liveborn singletons Denmark 1997–2016. Exclusion is by births where mothers used any of the investigated drug at any time prior to delivery. ORs adjusted for birth year, paternal age, income and education, and maternal age, smoking status and education, except for the sibling analysis. Separate models per drug. Exposure taken as binary: having at least one prescription in the 3-month preconception timeframe. Offspring numbers for the sibling analysis include exposed as well as unexposed offspring. SSRIs, selective serotonin reuptake inhibitors.
Table 3  EUROCAT subgroups (binary: ≥1) by drug class, all liveborn singletons, Denmark 1997–2016

| Birth defect category | None of the specified drugs (1 147 055) | Antipsychotics (4301) | Anxiolytics (4918) | Hypnotics and sedatives (5797) | Antidepressants (17 827) | (Benzo)diazepines (7349) | N05AH (1633) |
|-----------------------|------------------------------------------|-----------------------|-------------------|-----------------------------|-------------------------|------------------------|---------------|
| Digestive             | 0.22% (2471)                             | 0.28% (12)            | 0.12% (6)         | 0.19% (11)                  | 0.19% (33)              | 0.16% (11)            | 0.37% (6)     |
| Urinary               | 0.26% (3020)                             | 0.37% (16)            | 0.33% (16)        | 0.38% (22)                  | 0.29% (51)              | 0.40% (28)           | 0.73% (12)    |
| Heart                 | 0.70% (8069)                             | 0.77% (33)            | 0.79% (39)        | 0.78% (45)                  | 0.70% (125)             | 0.79% (56)           | 0.73% (12)    |
| Chromosomal           | 0.11% (1283)                             | ≤0.12% (≤5)           | ≤0.10% (≤5)       | ≤0.09% (≤5)                 | 0.11% (20)              | ≤0.07% (≤5)          | ≤0.30% (≤5)   |
| Limb                  | 0.93% (10 699)                           | 0.93% (40)            | 0.96% (47)        | 0.67% (39)                  | 0.94% (167)             | 0.91% (64)           | 1.16% (19)    |
| Nervous               | 0.11% (1305)                             | 0.19% (8)             | 0.14% (7)         | 0.16% (9)                   | 0.08% (15)              | 0.13% (9)            | ≤0.30% (≤5)   |
| Eye                   | 0.12% (1384)                             | ≤0.12% (≤5)           | 0.14% (7)         | ≤0.09% (≤5)                 | 0.12% (22)              | 0.11% (9)            | ≤0.30% (≤5)   |
| Genital               | 0.25% (2825)                             | 0.21% (9)             | 0.22% (11)        | 0.24% (14)                  | 0.30% (54)              | 0.24% (17)           | ≤0.30% (≤5)   |
| Oro-facial clefts     | 0.15% (1684)                             | 0.19% (8)             | ≤0.10% (≤5)       | 0.16% (9)                   | 0.13% (23)              | 0.11% (8)            | ≤0.30% (≤5)   |
| Other                 | 0.64% (7287)                             | 1.05% (45)            | 0.92% (45)        | 0.79% (46)                  | 0.80% (142)             | 0.91% (64)           | 1.29% (21)    |

Notice that offspring may appear in more than one category. Publication of numbers smaller than 5 not permitted. Classified as recommended in EUROCAT guide 1.4, section 3.3, pages 92–96.

**Power and detectable odds**

At 80% or 90% power, the minimum detectable OR was between 1.1 and 1.3 for the larger groups (11, 13 and 15) for antidepressants, benzodiazepines, anxiolytics, hypnotics and sedatives. For benzodiazepines (N05AH), minimum detectable ORs could be as high as 2 (table 4). Assuming a therapy adherence of 50%, minimum detectable ORs were approximately 1.3 for antipsychotics, approximately 1.5 for anti-anxiety drugs (table 3) and antidepressants (table 4). For antidepressants, the OR was 1.09 (0.96 to 1.25) after exclusion of births to mothers ever prescribed antidepressants (OR 1.22, 95% CI 1.14 to 1.30) and 1.22 (95% CI 1.14 to 1.30) after exclusion of births to mothers ever prescribed antidepressants (OR 1.22, 95% CI 1.14 to 1.30). This adjustment had little impact on the results. After multivariable adjustment, all 95% CIs included one (table 2). Results were similar in the siblings analysis (table 2). For antipsychotics, the ORs were 0.97 (0.89 to 1.05) and 0.94 (0.85 to 1.04), respectively (all liveborn singletons), and 0.95 (0.85 to 1.05) and 0.96 (0.85 to 1.09) after exclusion. There was a moderate but not statistically significant tendency towards higher birth defect risk among children whose fathers were prescribed antipsychotics (N05AH), which showed an AOR of 1.52 (95% CI 1.45 to 1.59) for all liveborn singletons, and 1.53 (95% CI 1.45 to 1.61) after exclusion of births to mothers ever prescribed antipsychotics (OR 1.52, 95% CI 1.45 to 1.60). The AOR was 1.52 (95% CI 1.45 to 1.60) after exclusion of births to mothers ever prescribed antipsychotics (OR 1.52, 95% CI 1.45 to 1.60).
Table 4 Minimum risks detectable as aberrant

| Drug class                          | N     | Assuming 100% therapy adherence | Assuming 50% therapy adherence |
|------------------------------------|-------|---------------------------------|--------------------------------|
|                                    |       | 80% power | 90% power | 80% power | 90% power |
| Antipsychotics (N05A)              | 4301  | 1.25      | 1.32      | 1.51      | 1.64      |
| Anxiolytics (N05B)                 | 4918  | 1.25      | 1.28      | 1.51      | 1.57      |
| Hypnotics and sedatives (N05C)     | 5797  | 1.22      | 1.25      | 1.45      | 1.51      |
| Diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH) | 1633  | 1.45      | 1.54      | 1.90      | 2.10      |
| Benzodiazepine-derived anxiolytics (N05BA) | 4742  | 1.25      | 1.28      | 1.51      | 1.57      |
| Benzodiazepines as hypnotics and sedatives (N05CD) | 1153  | 1.54      | 1.64      | 2.10      | 2.31      |
| (Benzodiazepines grouped (N05AH, N05BA or N05CD) | 7057  | 1.19      | 1.22      | 1.38      | 1.45      |
| Antidepressants (N06A)             | 17827 | 1.13      | 1.16      | 1.25      | 1.32      |
| SSRIs (N06AB)                      | 11902 | 1.16      | 1.19      | 1.32      | 1.38      |

Based on a univariate binomial model with population risk of 3.3% assuming a 1:10 exposed:unexposed ratio. The two rightmost columns assume a 50–50 mix between the population risk of 3.3% and the risk among the exposed.

DISCUSSION

Summary of findings

The current study found weak or null associations between offspring birth defects and prescriptions of common neurological drugs filled by the father during the 3 months preconception. The only medication group that suggested a possible association was diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH), which showed a moderately elevated AOR of 1.22 (0.97 to 1.54) for all liveborn singletons. The point estimate was similar in the sibling analysis, but reduced to 1.13 after excluding offspring whose mother had filled a prescription of any of the investigated drugs at any time prior to delivery. For SSRIs, a large group with the strongest prior evidence of associated sperm damage, the AOR was 0.94 (0.85 to 1.04) before exclusion and 0.96 (0.85 to 1.09) after exclusion. Results were similar when comparing exposed to unexposed siblings. The number of births with paternal exposure to each of the drugs was generally large enough to detect a what might be a clinically significant elevation in risk, for the larger groups even when assuming that only half the fathers took the medication that they had been prescribed.

Strengths and limitations

The design of a nationwide, registry-based cohort study allowed the inclusion of large numbers of fathers who were prescribed the investigated drugs just before conception and to ascertain whether their offspring had birth defects. The registries used are generally complete and of high quality, with (hospital) reimbursement generally depending on reporting and with cross-checks between registries in place. Further information can be found in references.10–13 Although our measure of paternal exposure was indirect—filling a prescription does not equate with taking the drugs—the study had power to overcome exposure misclassification. Dosage and exact timing of exposure were not considered, which could have biased our results towards the null.

We did not have information on paternal lifestyle factors, such as exercise or smoking, and there may have been maternal factors (e.g., genetic predisposition, lifestyle factors like exercise) for which we could not control. We saw significant differences in demographics between fathers prescribed drugs and those who were not. However, these factors are unlikely to have biased the results towards the null because that would require paternal drug prescriptions to correlate with protective maternal or paternal factors.

Even using registry data, there remains a possibility that offspring of fathers prescribed neurological drugs are less visible to the healthcare system because of the fathers’ psychological or psychiatrical ailments. This could result in reduced birth defect ascertainment for these offspring and hence bias the results towards (or even below) the null. Nevertheless, Denmark has universal healthcare with scheduled check-ups for newborns, both at birth and in the first year of life, and we restricted to birth defects classified by EUROCAT as major. Thus, it seems reasonable to suspect that the majority of birth defects would be diagnosed. However, if there was an association between a paternal medication and an earlier reproductive outcome (e.g., failure to fertilize, miscarriage), the effect on birth defects could be interpreted as bias towards the null.

Interpretation, possible mechanism, comparison with the literature

Although sperm DNA damage suggests a risk to offspring, this risk may not materialise if sperm with damaged DNA fail to fertilise an egg cell, if the oocyte corrects any DNA damage, if the conceptus fails to develop into a viable fetus or if the fetus is aborted. Hence, sperm damage could...
lead to subfertility or infertility, but not birth defects. As the Danish Medical Bi

rth Registry covers only pregnancies from week 20 onwards, further studies are necessary to explore this hypothesis.

Literature on paternal effects on offspring is limited. Certainly, it is reasonable to expect that the 9months a fetus spends developing in utero gives more scope for teratogenic effects from maternal exposure than preconception spermatogenic paternal contribution. Yet there is increasing evidence that sperm contributes more than DNA alone,24 and the early stages of pregnancy are also the most vulnerable stages with regard to birth defects.

The observation of a tendency towards increased risk in diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH) may be due to the disease rather than drug, although antipsychotics as a whole only very mildly tended towards an increased OR, while neither birth defects of the nervous system nor chromosomal birth defects were elevated in this group. However, a prior study did suggest a possible association between paternal diazepam and perinatal mortality and growth retardation.25 The attenuation of the point estimate seen when excluding births where mothers had been on any of these drugs may indicate confounding by maternal associations. However, if a significant share of the N05AH-exposed offspring were actually unexposed, because the father may not have taken the filled prescription, 1.22 may be an underestimate of the true association.

CONCLUSION

The current study found weak or null associations between prescriptions of neurological drugs (antipsychotics, anxiolytics, hypnotics and sedatives, antidepressants, and SSRIs, benzodiazepine-derived anxiolytics) filled by the father during the development of fertilising sperm (3months before conception) and birth defects in the offspring. Paternal use of diazepines, oxazepines, thiazepines and oxepines (as antipsychotics, N05AH) during the development of fertilising sperm may be associated with mildly elevated birth defect frequencies, although a maternal pathway is not excluded here and although this observation could be due to chance. As such, men can be counselled that these medications likely do not increase the risk of birth defects. Further studies are necessary to investigate whether these drugs lead to higher rates of stillbirths, early abortions or failure to fertilise, as well as the group N05AH.

Author affiliations

1Department of Epidemiology, Biostatistics and Biodemography, University of Southern Denmark, Odense, Denmark
2Interdisciplinary Center on Population Dynamics, University of Southern Denmark, Odense C, Denmark
3Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA
4Department of Environmental Medicine, University of Southern Denmark, Odense, Denmark
5Department of Growth and Reproduction, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
6Male Reproductive Medicine and Surgery, Department of Urology, Stanford University School of Medicine, Stanford, California, USA

Contributors ME, RL-J, NES, YL and TKJ designed the study. MW, YL and LT handled data and statistical analysis. MW wrote the first draft. All authors interpreted the results, revised the manuscript and approved the final version. MW is the guarantor of the article.

Funding This study was funded by NIH grant HD096468 (to ME).

Disclaimer The funder had no role in the study design, collection, analysis and interpretation of the data and in the writing of the report.

Competing interests YL reports grants from Merck, and personal fees from United Health Care, Nektar, and Gilead, outside the submitted work. ME reports advisorships for Sandstone Diagnostics, Dadi, Hannah and Underdog, which are fertility-related companies.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants, but registry studies are exempted in Denmark from IRB review. They are subject to strict regulations. They are executed on a secure server at Statistics Denmark, and only aggregate data are allowed to leave the server (tables, regression coefficients) after being controlled by someone else than the primary analyst.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data from Statistics Denmark cannot be made publicly available but can be applied for through the usual ways at DSt.dk. The grant proposal is summarised here: https://reporter.nih.gov/search/C3FoCZUipkCJsZsijQP4LA/ project-details/9385127#details

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Maarten Wensink http://orcid.org/0000-0001-6518-1015

REFERENCES

1 Safarnejad MR. Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay. J Urol 2008;180:2124–8.
2 Tanikutz C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. Fertil Steril 2010;94:1021–6.
3 Akasheh G, Sirati L, Noshad Kamran AR, et al. Comparison of the effect of sertraline with behavioral therapy on semen parameters in men with primary premature ejaculation. Urology 2014;83:800–4.
4 Koyuncu H, Serefoglu EC, Yencilek E, et al. Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res 2011;23:257–61.
5 Adler I-D, Schmid TE, Baumgarten A. Induction of aneuploidy in rodent and human sperm by multicolor fish after chronic exposure to diazepam. Mutat Res 2001;490:11–19.
Wensink M, Rizzi S, Jensen TK, et al. Paternal prescription medication before conception: a retrospective cohort study of all births in Denmark 1997–2017. Scand J Public Health 2021;49:884–90.

Kasman AM, Zhang CA, Li S, et al. Association of preconception paternal health on perinatal outcomes: analysis of U.S. claims data. Fertil Steril 2020;113:947–54.

Khundwala YS, Zhang CA, Lu Y, et al. The age of fathers in the USA is rising: an analysis of 168 867 480 births from 1972 to 2015. Hum Reprod 2017;32:2110–6.

Bliddal M, Broe A, Pottegård A, et al. The Danish medical birth register. Eur J Epidemiol 2018;33:27–36.

Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9.

Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the Danish national prescription registry. Int J Epidemiol 2017;46:798–f.

Lyng E, Sandegaard JL, Reboli M. The Danish national patient register. Scand J Public Health 2011;39:30–3.

EUROCAT. EUROCAT central registry uou. European surveillance of congenital Anomalities (EUROCAT 2013). In: EUROCAT guide 1.4: instruction for the registration of congenital anomalies. 11, 2019. https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1_4_version_28_DEC2018.pdf

Neto FTL, Bach PV, Najari BB, et al. Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol 2016;59:10–26.

van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by Chained equations in R. Journal of Statistical Software 2011;45:1–67.

Woods S. Generalized additive models, an introduction with R. 2 edn. New York: Chapman and Hall/CRC, 2017.

Harris BS, Bishop KC, Kemény HR, et al. Risk factors for birth defects. Obstet Gynecol Surv 2017;72:123–35.

Rynn L, Cragan J, Correa A, et al. Update on overall prevalence of major birth defects—Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep 2008;57:756–8.

Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update 2011;17:589–604.

Wasserman CR, Shaw GM, Selvin S, et al. Socioeconomic status, neighborhood social conditions, and neural tube defects. Am J Public Health 1998;88:1674–80.

R Development Core Team. R: a language and environment for statistical computing: R foundation for statistical computing, 2020.

Dupont WD, Plummer WD. Power and sample size calculations. A review and computer program. Control Clin Trials 1980;11:116–28.

Immler S. The sperm factor: paternal impact beyond genes. Heredity 2018;121:239–47.

Engeland A, Bjerre T, Daltveit AK, et al. Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340 000 pregnancies using Norwegian population-based databases. Br J Clin Pharmacol 2013;75:1134–41.